Market closed

Spero Therapeutics/$SPRO

14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX

About Spero Therapeutics

Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. Besides, it is also focused on SPR206, a next-generation polymyxin investigational product candidate, being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.

Ticker

$SPRO
Sector
Health Care
Trading on
NASDAQ

Industry

Biotechnology
Headquarters
Cambridge, United States

Employees

46
Website
sperotherapeutics.com

SPRO Metrics

BasicAdvanced
$53M
15.05
$0.06
0.63
-

$53M

0.63

$1.89

$0.92

220K

2.681

2.639

4.401

7.056

-0.57%

5.89%

15.047

0.491

0.81

0.81

-2.981

37.01%

-307.24%

82.83%

-71.04%

What the Analysts think about SPRO

Analyst Ratings

Analyst ratings (Buy, Hold, Sell) for Spero Therapeutics stock.

SPRO Financial Performance

Income Statement

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

SPRO Earnings Performance

Earnings per share (EPS)

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-

SPRO News

AllArticlesVideos
Spero Therapeutics Provides Business Update and Announces Interim Leadership Changes

Spero Therapeutics Provides Business Update and Announces Interim Leadership Changes

GlobeNewsWire·5 days ago
Spero Therapeutics Announces Third Quarter 2024 Operating Results and Provides a Business Update

Spero Therapeutics Announces Third Quarter 2024 Operating Results and Provides a Business Update

GlobeNewsWire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $SPRO

$

Sign up or log in to buy
Capital at risk
Market closed

Upcoming events

No upcoming events

FAQs

What’s the current market cap for Spero Therapeutics stock?

Spero Therapeutics (SPRO) has a market cap of $53M as of January 15, 2025.

What is the P/E ratio for Spero Therapeutics stock?

The price to earnings (P/E) ratio for Spero Therapeutics (SPRO) stock is 15.05 as of January 15, 2025.

Does Spero Therapeutics stock pay dividends?

No, Spero Therapeutics (SPRO) stock does not pay dividends to its shareholders as of January 15, 2025.

When is the next Spero Therapeutics dividend payment date?

Spero Therapeutics (SPRO) stock does not pay dividends to its shareholders.

What is the beta indicator for Spero Therapeutics?

Spero Therapeutics (SPRO) has a beta rating of 0.63. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.